medicilon.com.cnCrawled Nov 7, 2026
China Biologic announced FDA approval for clinical trials of CPX301, a GLP-1 receptor agonist dissolvable microneedle patch developed by Beijing Taide Pharmaceutical for weight management.
The Center for Drug Evaluation (CDE) listed Shiyujitan Group’s SYS6010 as a breakthrough therapy candidate for recurrent or metastatic head and neck squamous cell carcinoma after failure of immunotherapy and platinum-based chemotherapy.
North China Pharmaceutical received approval to conduct clinical trials for its hexavalent recombinant norovirus vaccine (Hansun yeast) targeting GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17 strains.
Medici supports GLP-1 drug development, having enabled 22 GLP-1-related compounds to enter clinical trials, including five licensed to external partners.
With over 20 years in preclinical CRO leadership, Medix offers a comprehensive CGT development platform covering CAR-T, TCR-T, CAR-NK, and TIL therapies, aligning with regulatory updates for targeted submissions.
Medix builds standardized technology platforms for ADC, mRNA, PROTAC, GLP-1, peptides, nucleic acids, and small-molecule drugs to support full-cycle development from idea to IND, shortening timelines and reducing risks.
Medix’s advanced drug development platform provides technical support for discovery and development, accelerating research breakthroughs and bringing innovative therapies to market faster.
Medix’s pain pharmacodynamics evaluation system integrates six model types: osteoarthritis, acute/chronic inflammatory pain, acute gout, neuropathic pain, postoperative pain, and chemotherapy-induced pain.
Medici’s Vice President of Drug Discovery Li Taiwei and Vice President of Business Development Xu Junhong will attend the 4th SMC x AimedBio ADC Conference in Seoul, South Korea, focusing on the latest advancements in antibody-drug conjugates (ADC).
Medici’s Senior Vice President of Business Development Dr. Bai Mingfeng, Vice President of Drug Discovery Dr. Steven Zhang, and Business Manager Dr. Gillian Sun will attend the American Chemical Society’s ACS Fall 2026 meeting.
The Medici ADC Forum brings together industry leaders and entrepreneurs in antibody-drug conjugates (ADC), nano-antibodies (NDC), and dual-payload ADC, discussing development and commercialization pathways.
In the first half of 2026, the company reported revenue of 761 million yuan, a 40.91% year-over-year increase, and net profit attributable to shareholders of 51.6 million yuan, up 6.45 billion yuan from the same period last year.
Medici is a contract research organization offering drug metabolism, preclinical studies, screening, chemistry, safety evaluation, and toxicology services.
Medici is a contract research organization offering drug metabolism, preclinical studies, screening, chemistry, safety evaluation, and toxicology services.
